Clinical Trials
5 trialsNCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT02467647 2015-06-10
HLJDT-2016
Wuhan University
Phase 1 Unknown
NCT00258245 2013-04-29
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00083460 2010-08-02
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
University of Arkansas
Phase 1 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed